Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Consolidated Net Income (2016 - 2026)

Lisata Therapeutics filings provide 12 years of Consolidated Net Income readings, the most recent being -$4.5 million for Q1 2026.

  • On a quarterly basis, Consolidated Net Income rose 4.97% to -$4.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$16.4 million, a 15.31% increase, with the full-year FY2025 number at -$16.6 million, up 17.01% from a year prior.
  • Consolidated Net Income hit -$4.5 million in Q1 2026 for Lisata Therapeutics, down from -$3.0 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of -$3.0 million in Q4 2025 to a low of -$6.2 million in Q1 2023.
  • Median Consolidated Net Income over the past 4 years was -$4.7 million (2025), compared with a mean of -$4.8 million.
  • Biggest five-year swings in Consolidated Net Income: decreased 25.25% in 2024 and later soared 35.92% in 2025.
  • Lisata Therapeutics' Consolidated Net Income stood at -$5.4 million in 2023, then grew by 14.07% to -$4.6 million in 2024, then soared by 35.92% to -$3.0 million in 2025, then tumbled by 51.96% to -$4.5 million in 2026.
  • The last three reported values for Consolidated Net Income were -$4.5 million (Q1 2026), -$3.0 million (Q4 2025), and -$4.2 million (Q3 2025) per Business Quant data.